Cowen Bets on Immunomedics Securing Accelerated Approval Even After Decreased Overall Survival Seen in IMMU-132 Abstract


Immunomedics, Inc. (NASDAQ:IMMU) left investors worried about its cancer asset IMMU-132 after revealing an abstract at yesterday’s annual San Antonio Breast Cancer Symposium¬† that showed overall survival (OS) has since stumbled from data seen in January. Why does Cowen analyst Phil Nadeau remain unfazed?

Story Continues